keyword
MENU ▼
Read by QxMD icon Read
search

Latanoprost

keyword
https://www.readbyqxmd.com/read/28342814/tear-cytokine-profile-of-glaucoma-patients-treated-with-preservative-free-or-preserved-latanoprost
#1
Jose M Martinez-de-la-Casa, Francisco Perez-Bartolome, Elena Urcelay, Jose L Santiago, Javier Moreno-Montañes, Pedro Arriola-Villalobos, Jose M Benitez-Del-Castillo, Julian Garcia-Feijoo
PURPOSE: To determine variations in cytokine levels of glaucoma patients treated either with preservative-free latanoprost or preserved latanoprost, relative to healthy individuals. METHODS: Tear samples were collected from 39 healthy subjects, 20 glaucoma patients treated with preserved latanoprost, and 20 patients treated with preservative-free latanoprost. A set of 27 inflammatory cytokines was analyzed in each group, including interleukin (IL)-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, eotaxin, fibroblast growth factor (FGF) basic, granulocyte colony stimulating factor (G-CSF), granulocyte monocyte colony stimulating factor (GM-CSF), interferon (IFN)-γ, interferon gamma-induced protein (IP)-10, monocyte chemo attractant protein (MCP)-1MCAF, macrophage inflammatory protein (MIP)-1α, MIP-1β, platelet-derived growth factor (PDGF)-BB, regulated on activation, normal T cell expressed and secreted (RANTES), tumor necrosis factor (TNF)-α and vascular endothelial growth factor (VEGF)...
March 22, 2017: Ocular Surface
https://www.readbyqxmd.com/read/28320481/cystoid-macular-edema-associated-with-preservative-free-latanoprost-after-uncomplicated-cataract-surgery-case-report-and-review-of-the-literature
#2
Olga E Makri, Foteini N Tsapardoni, Panagiotis Plotas, Nikistratos Ifantis, Paraskevi T Xanthopoulou, Constantine D Georgakopoulos
BACKGROUND: Cystoid macular edema associated with latanoprost administration has been reported in patients after complicated cataract surgery with coexisting risk factors. We present the first case of preservative free latanoprost associated cystoid macular edema that occurred many months after uncomplicated cataract surgery. CASE PRESENTATION: A 65-year old Caucasian female presented in the Outpatients Clinic complaining of reduced vision and metamorphopsia in the right eye...
March 20, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/28319936/correction-fixed-dose-combination-of-ar-13324-and-latanoprost-a-double-masked-28-day-randomised-controlled-study-in-patients-with-open-angle-glaucoma-or-ocular-hypertension
#3
(no author information available yet)
No abstract text is available yet for this article.
July 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28251075/intraocular-pressure-with-rebound-tonometry-and-effects-of-topical-intraocular-pressure-reducing-medications-in-guinea-pigs
#4
Yue Di, Xiu-Mei Luo, Tong Qiao, Na Lu
AIM: To investigate the intraocular pressure (IOP) of adult guinea pig eyes with rebound tonometry (RBT), and assess the effects of four distinctive topical IOP reducing medications including Carteolol, Brimonidine, Brinzolamide and Latanoprost. METHODS: The IOPs of twenty-four 12-week-old guinea pigs (48 eyes) were measured every two hours in one day with RBT as baselines. All the animals were then divided into four groups (Carteolol, Brimonidine, Brinzolamide and Latanaprost groups, n=6)...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28229536/the-physical-properties-of-generic-latanoprost-ophthalmic-solutions-are-not-identical
#5
Miriam Kolko, Peter Koch Jensen
PURPOSE: To compare various characteristics of Xalatan(®) and five generic latanoprost ophthalmic solutions. METHODS: Drop size, volume, pH values, buffer capacity, viscosity, hardness of bottles and costs were determined. Drop sizes were measured in triplicates by micropipettes, and the number of drops counted in three separate bottles of each generic product was determined. pH values were measured in triplicates by a calibrated pH meter. Buffer capacity was exploited by titrating known quantities of strong base into 2...
February 22, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28203189/a-mystery-of-bilateral-annular-choroidal-and-exudative-retinal-detachment-with-no-systemic-involvement-is-it-part-of-vogt-koyanagi-harada-disease-spectrum-or-a-new-entity
#6
Ibrahim Elaraoud, Walter Andreatta, Li Jiang, Kenan Damer, Jalil Al-Ibrahim
A 65-year-old Caucasian male presented to the eye emergency department with bilateral significant visual loss. He was otherwise healthy with no significant past medical history. Ophthalmic history was significant for chronic open-angle glaucoma, for which the patient was using latanoprost once daily to both eyes. There was no preceding history of trauma or ocular surgery and the patient was emmetropic. Two weeks prior to his presentation, he reported a headache, which settled spontaneously. Slit-lamp examination demonstrated bilateral keratic precipitates, bilateral significantly shallow anterior chamber, and bilaterally normal intraocular pressures of 16 mm Hg...
January 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28165835/assessment-of-the-anterior-chamber-flare-and-macular-thickness-in-patients-treated-with-topical-antiglaucomatous-drugs
#7
Fırat Selen, Oya Tekeli, Özge Yanık
PURPOSE: To determine the changes in the anterior chamber flare and central macular thickness (CMT) under topical antiglaucomatous therapy. METHODS: This study included 121 eyes of 73 patients and 36 eyes of 18 controls. Glaucoma patients were divided into 3 groups (timolol maleate, latanoprost, and bimatoprost). Control eyes did not receive any medications. Flare and CMT measurements were performed at baseline and follow-up visits (15th day, and 1st, 3rd, 6th, and 12th month)...
February 6, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28164422/effect-of-prophylactic-topical-hypotensive-medications-in-reducing-the-incidence-of-postoperative-ocular-hypertension-after-phacoemulsification-in-dogs
#8
D Dustin Dees, Kate J Spahn, Lynsey Smith Wagner, Andrew Greller, Danielle Paglia, Micki D Armour, Richard Madsen
OBJECTIVE: To determine whether topical hypotensive medications prevent postoperative ocular hypertension (POH) after phacoemulsification. ANIMALS STUDIED: 52 client-owned dogs (88 eyes). PROCEDURES: Diabetic and nondiabetic dogs having undergone phacoemulsification were included in this retrospective study. The control group received no ocular hypotensive medications. The treatment groups received latanoprost, dorzolamide, or dorzolamide/timolol, beginning immediately after surgery, for 2-week duration...
February 6, 2017: Veterinary Ophthalmology
https://www.readbyqxmd.com/read/28146132/a-novel-convergent-synthesis-of-the-potent-antiglaucoma-agent-tafluprost
#9
Małgorzata Krupa, Michał Chodyński, Anna Ostaszewska, Piotr Cmoch, Iwona Dams
Tafluprost (AFP-168, 5) is a unique 15-deoxy-15,15-difluoro-16-phenoxy prostaglandin F2α (PGF2α) analog used as an efficacious ocular hypotensive agent in the treatment of glaucoma and ocular hypertension, as monotherapy, or as adjunctive therapy to β-blockers. A novel convergent synthesis of 5 was developed employing Julia-Lythgoe olefination of the structurally advanced prostaglandin phenylsulfone 16, also successfully applied for manufacturing of pharmaceutical grade latanoprost (2), travoprost (3) and bimatoprost (4), with an aldehyde ω-chain synthon 17...
January 31, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28081184/intraocular-pressure-lowering-effect-of-latanoprost-is-hampered-by-defective-cervical-lymphatic-drainage
#10
Young Kook Kim, Kyeong Ik Na, Jin Wook Jeoung, Ki Ho Park
PURPOSE: To evaluate whether defects in cervical lymphatic drainage influence the intraocular pressure (IOP)-lowering effect of latanoprost in patients with primary open-angle glaucoma (POAG) who have undergone unilateral radical neck dissection (uRND). METHODS: We enrolled (1) bilateral POAG patients who had started (bilateral) latanoprost (0.005%) monotherapy prior to their uRND and (2) treatment-naïve, bilateral glaucoma suspects (GSs) who had undergone the same surgery...
2017: PloS One
https://www.readbyqxmd.com/read/28053501/fixed-combination-of-travoprost-and-timolol-maleate-reduces-intraocular-pressure-in-japanese-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension-analysis-by-prostaglandin-analogue
#11
Tadashi Nakano, Shiro Mizoue, Nobuo Fuse, Aiko Iwase, Shun Matsumoto, Keiji Yoshikawa
BACKGROUND: We have shown a decrease in mean intraocular pressure (IOP) by switching to travoprost/timolol fixed combination (TTFC) in subjects receiving prostaglandin analogue (PGA) monotherapy and requiring additional medication in a previous report. For analyzing factors affecting IOP reduction, baseline IOP and preceding PGA were selected as statistically and clinically significant factors. In this report, we examine IOP-lowering effect and adverse drug reactions by preceding PGA...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27994439/impact-of-prostaglandin-glaucoma-drops-on-platelet-activating-factor-action-an-in-vitro-study
#12
Marilita M Moschos, Eirini Nitoda, Irini P Chatziralli, Georgios D Panos, Constantinos A Demopoulos
AIM: The aim of this study was to investigate the effect of different prostaglandin analogs on platelet-activating factor (PAF) levels. METHODS: Three prostaglandin analogs were selected: bimatoprost 0.3 mg/mL, latanoprost 50 μg/mL, and tafluprost 15 μg/mL. Each drug sample was tested for its ability to cause platelet aggregation, which was measured as PAF-induced aggregation, before and after the addition of various concentrations of the examined sample, creating a linear curve of percentage inhibition (ranging from 0% to 100%) versus different concentrations of the sample...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27913991/24-hour-efficacy-and-ocular-surface-health-with-preservative-free-tafluprost-alone-and-in-conjunction-with-preservative-free-dorzolamide-timolol-fixed-combination-in-open-angle-glaucoma-patients-insufficiently-controlled-with-preserved-latanoprost-monotherapy
#13
Anastasios-Georgios Konstas, Konstadinos G Boboridis, Paraskevas Kapis, Konstantinos Marinopoulos, Irini C Voudouragkaki, Dimitrios Panayiotou, Dimitrios G Mikropoulos, Eirini Pagkalidou, Anna-Bettina Haidich, Andreas Katsanos, Luciano Quaranta
INTRODUCTION: The aim of the present study was to evaluate the 24-h efficacy, tolerability, and ocular surface health with preservative-free (PF) tafluprost and a PF triple drug regimen comprising tafluprost and dorzolamide/timolol fixed combination (DTFC) in open-angle glaucoma patients who were insufficiently controlled with preserved branded or generic latanoprost monotherapy and who exhibited signs or symptoms of ocular surface disease (OSD). METHODS: Prospective, observer-masked, crossover, comparison...
January 2017: Advances in Therapy
https://www.readbyqxmd.com/read/27862086/correlations-of-afap1-gmds-and-ptgfr-gene-polymorphisms-with-intra-ocular-pressure-response-to-latanoprost-in-patients-with-primary-open-angle-glaucoma
#14
X-J Cui, A-G Zhao, X-L Wang
WHAT IS KNOWN AND OBJECTIVE: Genomewide association studies have identified a number of genetic variants that are associated with the development of primary open-angle glaucoma (POAG). This study aimed to explore possible correlations of common single nucleotide polymorphisms (SNPs) in AFAP1, GMDS and PTGFR genes with intra-ocular pressure (IOP) response to latanoprost in POAG patients. METHODS: From January 2012 to December 2014, 135 patients with POAG were enrolled into our study...
February 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/27859240/the-neuroprotective-effect-of-latanoprost-acts-via-klotho-mediated-suppression-of-calpain-activation-after-optic-nerve-transection
#15
Kotaro Yamamoto, Kota Sato, Masayoshi Yukita, Masayuki Yasuda, Kazuko Omodaka, Morin Ryu, Kosuke Fujita, Koji M Nishiguchi, Shigeki Machida, Toru Nakazawa
Latanoprost was first developed for use in glaucoma therapy as an ocular hypotensive agent targeting the prostaglandin F2α (FP) receptor. Subsequently, latanoprost showed a neuroprotective effect, an additional pharmacological action. However, although it is well-known that latanoprost exerts an ocular hypotensive effect via the FP receptor, it is not known whether this is also true of its neuroprotective effect. Klotho was firstly identified as the gene linked to the suppression of aging phenotype: the defect of klotho gene in mice results aging phenotype such as hypokinesis, arteriosclerosis, and short lifespan...
February 2017: Journal of Neurochemistry
https://www.readbyqxmd.com/read/27829990/analysis-of-the-effects-of-preservative-free-tafluprost-on-the-tear-proteome
#16
Sebastian Funke, Sabine Beck, Katrin Lorenz, Marion Kotterer, Dominik Wolters, Natarajan Perumal, Norbert Pfeiffer, Franz H Grus
The purpose of the present study was to assess the ocular surface health status in primary open angle glaucoma (POAG) patients switching from topical application of preserved latanoprost (LT) to preservative-free tafluprost (PFT) by tear proteomic monitoring. Tear fluid of POAG patients showing dry eye symptoms, using LT and switching to PFT as well as tear fluid of healthy controls has been examined. Tear proteome dynamics was monitored over 24 weeks in a first mass spectrometric explorative analysis in a small POAG patient cohort (N = 3)...
2016: American Journal of Translational Research
https://www.readbyqxmd.com/read/27828896/new-classes-of-glaucoma-medications
#17
REVIEW
Emily M Schehlein, Gary D Novack, Alan L Robin
PURPOSE OF REVIEW: To discuss recent advances in the medical management of glaucoma and to highlight future medical therapies currently in development. RECENT FINDINGS: In 1996, latanoprost (Xalatan) was approved in the United States as a new chemical entity and new class (prostaglandin analogs) for the topical treatment of ocular hypertension and glaucoma. In the period from the late 1990s-2010s, while there were additional new chemical entities, fixed dose combinations, and formulation improvements, there were no new classes of ocular hypotensive medications approved worldwide...
March 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27828721/change-in-central-corneal-thickness-after-the-discontinuation-of-latanoprost-in-normal-tension-glaucoma-change-in-central-corneal-thickness-after-stop-of-latanoprost
#18
Romi Yoo, Youn A Choi, Byung Joo Cho
PURPOSE: To assess the impact of latanoprost on central corneal thickness (CCT) after ceasing medication in patients with normal tension glaucoma (NTG). METHODS: A total of 46 eyes from 46 NTG patients, and 44 eyes from 44 individuals with glaucoma suspect (controls), were included in this retrospective study. Newly diagnosed early NTG patients (visual field mean deviation >-6.00) were administered latanoprost 0.005% monotherapy once a day. CCTs were measured by ultrasound pachymetry before treatment, for 5 years during treatment, and for 2 years after ceasing treatment...
January 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27800256/transpupillary-argon-laser-cyclophotocoagulation-in-a-refractory-traumatic-glaucoma-patient-with-aphakia-and-aniridia
#19
Umut Duygu Uzunel, Berna Yüce, Tuncay Küsbeci, Halil Ateş
We present a case of transpupillary argon laser cyclophotocoagulation (TALC) in a patient with traumatic aniridia and aphakia secondary to blunt trauma who had previous bilateral trabeculectomy. Four months after the trauma the patient's intraocular pressure (IOP) rose to 35 mmHg despite topical antiglaucomatous medication. Inferior 180 degrees cyclophotocoagulation was performed with transpupillary argon laser in the first session and his IOP fell to values of 12-17 mmHg. Twelve weeks after TALC, his IOP rose to 22 mmHg and we had to apply TALC to the residual ciliary processes...
January 2016: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/27799736/efficacy-and-tolerability-of-benzalkonium-chloride-free-travoprost-in-glaucoma-patients-switched-from-benzalkonium-chloride-preserved-latanoprost-or-bimatoprost
#20
Julian García-Feijoo, Francisco J Muñoz-Negrete, Douglas A Hubatsch, Gemma C Rossi
INTRODUCTION: The preservative benzalkonium chloride (BAK) is used to preserve several topical, intraocular pressure (IOP)-lowering glaucoma medications but can cause tolerability concerns that may lead to decreased adherence to treatment and ultimately diminish the effectiveness of IOP control. The study aimed to determine the efficacy and tolerability of BAK-free travoprost preserved with polyquaternium-1 in glaucoma patients switched from BAK-preserved latanoprost or bimatoprost. METHODS: This 12-week, open-label study was conducted in Europe between December 2011 and February 2013...
2016: Clinical Ophthalmology
keyword
keyword
121100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"